ライフサイエンスコーパス: lymphadenopathy

1 pulmonary nodules, skeletal metastases, and lymphadenopathy).

2 ystis jirovecii pneumonitis, and generalized lymphadenopathy.

3 stis spreads and thus leads to this striking lymphadenopathy.

4 h T1-2 primary breast cancer and no palpable lymphadenopathy.

5 of the left breast with no palpable axillary lymphadenopathy.

6 ls neither palpable breast mass nor axillary lymphadenopathy.

7 months later demonstrated enlarging cervical lymphadenopathy.

8 d night sweats; imaging revealed generalized lymphadenopathy.

9 amination of bilateral hilar and mediastinal lymphadenopathy.

10 product of lymphoproliferation/inflammatory lymphadenopathy.

11 berculosis would be based primarily on hilar lymphadenopathy.

12 ce, although such rescue ultimately leads to lymphadenopathy.

13 ude autoimmune cytopenias, organomegaly, and lymphadenopathy.

14 ms such as fever, maculopapular rash, and/or lymphadenopathy.

15 peripheral CD4(+) T cells and development of lymphadenopathy.

16 se with high-risk genomic features and bulky lymphadenopathy.

17 tent with the development of lymphopenia and lymphadenopathy.

18 ssessed for presence of pleural effusions or lymphadenopathy.

19 al desquamation, strawberry tongue, cervical lymphadenopathy.

20 eveloped an atypical phenotype with rash and lymphadenopathy.

21 iltrate, and CD62L correlated with extent of lymphadenopathy.

22 pendent antibody responses, splenomegaly and lymphadenopathy.

23 dy-mediated autoimmune cytopenias (AICs) and lymphadenopathy.

24 x-mediated nephritis and exhibit progressive lymphadenopathy.

25 with splenomegaly, hepatomegaly, and severe lymphadenopathy.

26 anges in the extremities, rash, and cervical lymphadenopathy.

27 be time dependent from the clinical onset of lymphadenopathy.

28 anted in order to determine the cause of the lymphadenopathy.

29 es of chemotherapy and to all sites of bulky lymphadenopathy.

30 characterised by fever, rash, headache, and lymphadenopathy.

31 performed in 247 patients with cervicofacial lymphadenopathy.

32 ion correlated with the presence of clinical lymphadenopathy.

33 hography was also seen in acute inflammatory lymphadenopathy.

34 fever, weight loss, hepatosplenomegaly, and lymphadenopathy.

35 in the lungs along with necrotic mediastinal lymphadenopathy.

36 control to provide nonmalignant inflammatory lymphadenopathy.

37 ion in the right parotid gland, and cervical lymphadenopathy.

38 % reported weight loss, 40% fatigue, and 21% lymphadenopathy.

39 nation revealed no palpable mass or axillary lymphadenopathy.

40 kable for bulky cervical and supraclavicular lymphadenopathy.

41 amination revealed also ipsilateral cervical lymphadenopathy.

42 differentiate melanoma metastasis from other lymphadenopathies.

43 , constitutional symptoms (100%), peripheral lymphadenopathy (100%), splenomegaly (72%), hepatomegaly

44 Further, 16% had eschar, 29% had lymphadenopathy, 100% had gastrointestinal symptoms, 34%

45 ic Castleman's disease included multicentric lymphadenopathy (128/128), anaemia (79/91), elevated C-r

46 mass-like consolidation (20%), intrathoracic lymphadenopathy (16%), pleural effusion (12%), reticular

47 t, the patient developed non-tender cervical lymphadenopathy 2 days after a reduction in prednisone d

48 cupying lesions (35%); abdominal/mediastinal lymphadenopathy (20%), ocular disease (18%) and multifoc

49 cupying lesions (35%), abdominal/mediastinal lymphadenopathy (20%), ocular disease (18%), and multifo

50 ry nodules (31.4%), mediastinal and/or hilar lymphadenopathy (23%), mass-like consolidation (17%), pl

51 ealed bilateral cervical and supraclavicular lymphadenopathy (6 x 5 cm with a standardized uptake val

52 ealed bilateral cervical and supraclavicular lymphadenopathy (6 x 5 cm).

53 with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5

54 In patients with residual lymphadenopathy, a lack of abnormal 18F-FDG uptake in th

55 iodic fever syndrome and severe intermittent lymphadenopathy-a condition we term 'cleavage-resistant

56 ia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis,

57 ermed CD28-DeltaTreg mice), characterized by lymphadenopathy, accumulation of activated T cells, and

58 tumors presented clinically with generalized lymphadenopathy, advanced stage, and poor outcome (5-yea

59 tion allergies, in the incidence of fever or lymphadenopathy after vaccination, or in the dilution of

60 All patients presented with lymphadenopathy and 11% also had extranodal disease.

61 lance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic mass with possi

62 -DeltaTreg mice prevented the development of lymphadenopathy and CD4(+) T cell activation, and autoim

63 l T cell manifestations persisted, including lymphadenopathy and cellular infiltrates of skin and liv

64 Conversely, lymphadenopathy and collapse had significant association

65 On the other hand, lymphadenopathy and collapse were closely associated wit

66 d torso fluorodeoxyglucose PET/CT (to assess lymphadenopathy and distant metastases) are used to assi

67 black woman diagnosed due to abdominal pain, lymphadenopathy and fever.

68 The etiology of the lymphadenopathy and follicular hyperplasia associated wi

69 peaked 10 days postinfection, while minimal lymphadenopathy and higher glycolytic activity were obse

70 Lymphadenopathy and immune activation in the axillary ly

71 he skin and lungs, accompanied by peripheral lymphadenopathy and increased differentiation of skin-tr

72 ntrols, PD-L1/2(-/-)LDLR(-/-) mice had iliac lymphadenopathy and increased numbers of activated CD4(+

73 etains more cells at these sites, leading to lymphadenopathy and massive bystander activation that ch

74 abdomen, and pelvis was requested to depict lymphadenopathy and organomegaly.

75 the parenchymal lung, including mediastinal lymphadenopathy and pericardial effusion, showed no stat

76 stology was predominantly angioimmunoblastic lymphadenopathy and PTCL not otherwise specified.

77 The disease presented as localized lymphadenopathy and showed a favorable response to chemo

78 Reductions in lymphadenopathy and splenomegaly are seen within weeks a

79 LPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a chara

80 ule (TRAF2DN), which mimics TRAF1, developed lymphadenopathy and splenomegaly due to polyclonal B cel

81 showed an absence of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival.

82 nt female MRL/lpr mice developed exacerbated lymphadenopathy and splenomegaly, higher serum anti-chro

83 e in peripheral B cells, which culminates in lymphadenopathy and splenomegaly, hypergammaglobulinemia

84 Lymphadenopathy and splenomegaly, which are characterist

85 n addition, these animals displayed systemic lymphadenopathy and splenomegaly.

86 e, disappearance of fever, and regression of lymphadenopathy and splenomegaly.

87 Most patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and

88 tic monoclonal antibody to CD137 (2A) blocks lymphadenopathy and spontaneous autoimmune diseases in F

89 e shown that Sle2c1 increases lpr-associated lymphadenopathy and T cell-mediated pathology.

90 to a limited degree, the ability to suppress lymphadenopathy and T helper cell type 2 activation.

91 ed in the differential diagnosis of inguinal lymphadenopathy and the diagnosis is possible with cytop

92 pancies were seen most commonly in detecting lymphadenopathy and visceral metastases.

93 tive lymphocyte apoptosis results in chronic lymphadenopathy and/or splenomegaly associated with auto

94 th acute febrile illness, systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly

95 e, 1 had miliary tuberculosis (TB), 2 had TB lymphadenopathy, and 1 had active pulmonary TB.

96 teral ovarian masses, pelvic and para-aortic lymphadenopathy, and a 4-cm omental tumor; in addition,

97 ickening involving the base of the appendix, lymphadenopathy, and appendiceal diameter.

98 inent findings including hepatitis, cervical lymphadenopathy, and arthralgia.

99 inflammation, dermatological abnormalities, lymphadenopathy, and cytomegalovirus disease.

100 e and size of pleural effusions and ascites, lymphadenopathy, and distant metastases.

101 ntibodies, exhibited marked splenomegaly and lymphadenopathy, and elevated serum IL-6.

102 high fever, rash, mucositis, conjunctivitis, lymphadenopathy, and extremity changes are superficially

103 ous liver enhancement, biliary duct changes, lymphadenopathy, and findings of portal hypertension.

104 ese episodes included bowel wall thickening, lymphadenopathy, and focal masses.

105 e significantly more likely to have fatigue, lymphadenopathy, and headache, as well as a longer durat

106 h P/EP CMV, symptoms including splenomegaly, lymphadenopathy, and hepatomegaly were associated with n

107 Fever, lymphadenopathy, and hepatosplenomegaly were often obser

108 On examination, she had scattered bruising, lymphadenopathy, and hepatosplenomegaly.

109 pical signs of MAIDS including splenomegaly, lymphadenopathy, and hypergammaglobulinemia.

110 transitional B cells and senescent T cells, lymphadenopathy, and immune deficiency (activated PI3Kde

111 inal lymphangiectasia, mesenteric lymph node lymphadenopathy, and lymphangiogenesis in both the mesen

112 on to splenomegaly, generalized or worrisome lymphadenopathy, and malignancy, especially lymphoma.

113 time, they developed severe splenomegaly and lymphadenopathy, and most animals also developed leukemi

114 Four infants had rash, lymphadenopathy, and oligoclonal populations of T cells

115 e responses to mitogens or who develop rash, lymphadenopathy, and oligoclonal T cells.

116 Hepatitis, lymphadenopathy, and other inflammatory sequelae are adv

117 RM, inducing B cell hyperplasia, persistent lymphadenopathy, and persistent infection in these anima

118 cterized by fever, tachycardia, hypotension, lymphadenopathy, and pruritus.

119 the most common adverse events being fever, lymphadenopathy, and rash.

120 and lacrimal and salivary glands pathology, lymphadenopathy, and splenomegaly are dramatically suppr

121 ing rapid improvement in autoimmune disease, lymphadenopathy, and splenomegaly within 1 to 3 months o

122 (skin, salivary and lacrimal glands, lungs, lymphadenopathy, and splenomegaly) is equivalent in ICOS

123 ncluding reductions in leukemia cell counts, lymphadenopathy, and splenomegaly.

124 ealed progressive pelvic and retroperitoneal lymphadenopathy, and the patient enrolled in a clinical

125 Transgenic mice showed lymphadenopathy, and transgenic T cells displayed increa

126 der characterized by chronic fatigue, fever, lymphadenopathy, and/or hepatosplenomegaly, associated w

127 The determinants of HIV-1-associated lymphadenopathy are poorly understood.

128 mmon lesions of the adrenal gland and showed lymphadenopathy around the major vessels of the abdomen.

129 Stat3 CKO mice developed cervical lymphadenopathy as well as a mild ileocolitis that persi

130 creased serum immunoglobulin G2a levels, and lymphadenopathy associated with increased gamma interfer

131 senteric involvement, and supradiaphragmatic lymphadenopathy at CT were associated with BRCA mutation

132 observed only in patients who had developed lymphadenopathy at least 4 months earlier.

133 of marginal zone macrophages, splenomegaly, lymphadenopathy, autoantibodies (including anti-DNA IgG)

134 lopment of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease.

135 Here we show that, in patients with lymphadenopathy, autocrine VEGF and alpha(4)beta(1) inte

136 riety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoi

137 optotic functions of RIPK3 contribute to the lymphadenopathy, autoimmunity, and excess cytokine produ

138 s macaques developed fever, classic eschars, lymphadenopathy, bacteremia, altered liver function, inc

139 Patients without bulky lymphadenopathy, BCRi-refractory CLL, or an adverse muta

140 udarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemt

141 aemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression wit

142 These mice seem immunocompetent but develop lymphadenopathy by four months of age marked by accumula

143 IgG1 and IgG2a, and reduced skin lesions and lymphadenopathy, compared with control mice.

144 The negative smear group featured lymphadenopathy, consolidation, collapse and nodular inf

145 transplantation included eosinophilia, rash, lymphadenopathy, development of CD4-CD8- peripheral T ce

146 -/-) mice manifested severe splenomegaly and lymphadenopathy, dramatically increased proinflammatory

147 th increased distal ileum wall thickness and lymphadenopathy during the illness period.

148 ult in an individual who has recent onset of lymphadenopathy (e.g., within 2 to 3 months of sera samp

149 patients had rash or eschar, eight (29%) had lymphadenopathy, eight (29%) had gastrointestinal sympto

150 valuation for abdominopelvic retroperitoneal lymphadenopathy, either with imaging alone or with patho

151 f B-cell hyperactivity such as splenomegaly, lymphadenopathy, elevated serum IL-6, elevated serum aut

152 lesion, Castleman disease, organomegaly (or lymphadenopathy), endocrinopathy, edema (peripheral edem

153 ifestations were noted: fever, sialadenitis, lymphadenopathy, erythema nodosum, leukocytoclastic vasc

154 usions, linear opacities, septal thickening, lymphadenopathy, extent of parenchymal involvement, and

155 the formation of satellite lesions, regional lymphadenopathy, fever, headache, nausea, muscle aches,

156 were observed in patients who had developed lymphadenopathy from <1 month to 17 months prior to the

157 tation of the Fas death receptor, is massive lymphadenopathy from aberrant expansion of CD4(-)CD8(-)

158 d by hypergammaglobulinemia, autoantibodies, lymphadenopathy, glomerulonephritis, and vasculitis.

159 Lymphadenopathy > or = 5 cm, but not cytogenetic abnorma

160 In multiple regression analyses, bulky lymphadenopathy (>=5 cm) and refractoriness to B-cell re

161 These included splenomegaly, lymphadenopathy, hepatomegaly, multifocal hepatitis, ane

162 Rare cases are disseminated with lymphadenopathy, hepatosplenomegaly, and a leukemic phas

163 defective Fas-mediated apoptosis, leading to lymphadenopathy, hepatosplenomegaly, and an increased nu

164 ifest in childhood with chronic nonmalignant lymphadenopathy, hepatosplenomegaly, and recurring multi

165 ALPS) is characterized by childhood onset of lymphadenopathy, hepatosplenomegaly, autoimmune cytopeni

166 ion syndrome of susceptibility to infection, lymphadenopathy, hepatosplenomegaly, developmental delay

167 d hyperattenuation on arterial phase images, lymphadenopathy, heterogeneity, extrahepatic metastases,

168 algorithm with predictive features including lymphadenopathy, high diffusion-weighted imaging signal

169 -infected C57BL/6 mice develop splenomegaly, lymphadenopathy, hypergammaglobulinemia, and immunodefic

170 type MCD, including splenomegaly, multifocal lymphadenopathy, hypergammaglobulinemia, and plasmacytos

171 Patients with isolated mediastinal lymphadenopathy (IML) are a common presentation to physi

172 tiation resulted in reduced splenomegaly and lymphadenopathy, impaired expansion and activation of T

173 ns elicited productive viral replication and lymphadenopathy in a dose-dependent fashion.

174 to distinct symptoms of recurrent fevers and lymphadenopathy in an autosomal-dominant manner.

175 Lymphadenopathy in autoimmune and other lymphoproliferat

176 cells, and showed reduced autoreactivity and lymphadenopathy in C57BL/6/lpr, and reduced mortality in

177 Lymphadenopathy in children for which no infectious or m

178 icular lymphoma (FL) presenting as localized lymphadenopathy in children.

179 ut not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion th

180 intrahepatic bile ducts in 17, and abdominal lymphadenopathy in eight.

181 as well as retrocrural and internal mammary lymphadenopathy in Hodgkin's lymphoma than in sarcoidosi

182 atients, the disease is caused by mesenteric lymphadenopathy in response to (viral) infection.

183 Tumor-reactive lymphadenopathy in SLNs has been observed for decades, b

184 e development of splenomegaly accompanied by lymphadenopathy in some mice.

185 19), mesenteric involvement (OR = 7.10), and lymphadenopathy in supradiaphragmatic (OR = 2.83) and su

186 used by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew becau

187 ished disease results in rapid regression of lymphadenopathy, in part because of apoptosis of the mal

188 veral hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and

189 arkedly delayed the onset of proteinuria and lymphadenopathy, increased survival, and reduced levels

190 Despite the lack of measurable lymphadenopathy, infection was associated with an increa

191 tor autoantibodies, total serum Ig isotypes, lymphadenopathy, inflammatory infiltrates in the salivar

192 d core biopsy in patients with head and neck lymphadenopathy is a safe outpatient procedure that has

193 c ultrasound is useful in staging NSCLC when lymphadenopathy is present on a computed tomography (CT)

194 cant difference between mean ADC value of 12 lymphadenopathies (LAP) associated with inflammatory bre

195 risk-stratification model, patients who had lymphadenopathy less than 5 cm and no comorbidities had

196 BALB/c mice also developed lymphadenopathy, liver dysfunction, and decreased NK cel

197 Lymphadenopathy (LN) is the most common clinical manifes

198 Each presented with persistent fevers, bulky lymphadenopathy, massive hepatosplenomegaly, and severe

199 Ag-induced peripheral T cell deletion, their lymphadenopathy may result from unrestrained homeostatic

200 y in inguinal and internal iliac nodes, with lymphadenopathy measuring up to 3.5 cm.

201 was associated with hypermetabolic symmetric lymphadenopathy (median maximal standardized uptake valu

202 EUS detected malignant mediastinal lymphadenopathy more frequently in patients with lower l

203 t Rabgef1-/- mice also develop splenomegaly, lymphadenopathy, myeloid hyperplasia, and high levels of

204 ations included fungemia (n = 2), multifocal lymphadenopathy (n = 2), and necrotizing pneumonia (n =

205 Masses (n = 2), lymphadenopathy (n = 2), areas of consolidation (n = 2),

206 e 1b study, patients had improved peripheral lymphadenopathy (n = 2), lung function (n = 1), thromboc

207 l bascule (n=1), ileus (n=1), and metastatic lymphadenopathy (n=1).

208 ia (n=9), fibrofatty proliferation (n=8) and lymphadenopathy (n=28).

209 events judged related to study product were lymphadenopathy (n=9) and hypoaesthesia (n=2).

210 In patients without residual lymphadenopathy, neck dissection may be withheld safely.

211 tis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis have also b

212 nts presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremi

213 ntly increased local immune infiltration and lymphadenopathy of the draining lymph node.

214 in unprotected animals was rapid and severe lymphadenopathy of the mediastinal lymph node cluster, w

215 terlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the chest comp

216 Lack of residual lymphadenopathy on CT had an NPV of 96%.

217 ography (CT), but its role in the absence of lymphadenopathy on CT has not been well defined.

218 ients with NSCLC with absence of mediastinal lymphadenopathy on CT were enrolled and followed prospec

219 ) in staging NSCLC in absence of mediastinal lymphadenopathy on CT.

220 y had elevated ACE, lymphopenia, and bihilar lymphadenopathy on CXR.

221 The presence of lymphadenopathy on physical examination was the most use

222 elvis showed no evidence for retroperitoneal lymphadenopathy or distant metastases.

223 ly subclinical but in some patients cervical lymphadenopathy or ocular disease can be present.

224 ), weight loss of >10% (OR, 10.0; P = .001), lymphadenopathy (OR 6.8; P = .002), HIV infection (OR, u

225 ia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly).

226 ndritic cells and did not have splenomegaly, lymphadenopathy, or inflammation in multiple organs.

227 nodules, vascular encasement, peripancreatic lymphadenopathy, or metastases.

228 iomata, particularly with systemic symptoms, lymphadenopathy, or other benign vascular endothelial gr

229 -cell lymphoproliferative disorder including lymphadenopathy/organomegaly.

230 elanoma lymph node metastases from the other lymphadenopathies (P < .05 for both) in vivo, whereas FD

231 per quadrant (P = .0003), supradiaphragmatic lymphadenopathy (P = .0004), more peritoneal disease sit

232 creased plasma galectin-3 levels (P = .001), lymphadenopathy (P = .04), total IgG level increase (P =

233 d by a CD4cre transgene led to age-dependent lymphadenopathy partly because of abnormal expansion of

234 pr animals showed a significant reduction in lymphadenopathy, pathogenic autoantibodies, and end-orga

235 In contrast to residual lymphadenopathy, persisting splenomegaly does not impact

236 rter, mutations in which cause histiocytosis-lymphadenopathy plus syndrome, a group of conditions wit

237 mice develop a lupus-like disease as well as lymphadenopathy, polyclonal lymphocyte activation, and a

238 ociated lymphoid tissue (NALT) plus cervical lymphadenopathy prior to bacteremic dissemination.

239 for evaluation of rapidly enlarging cervical lymphadenopathy, progressive dyspnea, fatigue, night swe

240 flammatory condition characterized by fever, lymphadenopathy, rash, arthritis, and serositis.

241 Headache, joint problems, diarrhea, and lymphadenopathy rates were significantly higher post-vac

242 in bone marrow, liver and spleen without any lymphadenopathy (referred to as BLS-type DLBCL), which i

243 58 of 103 patients, 56%) was associated with lymphadenopathy (relative risk [RR]: 1.7; 95% confidence

244 Simvastatin also reduced the lymphadenopathy, renal disease, and proinflammatory cyto

245 lopment of B-cell hyperplasia and persistent lymphadenopathy resembling multicentric Castleman diseas

246 more headache, joint problems, diarrhea, and lymphadenopathy, respectively, after MMR3.

247 tations; all but 1 patient had a decrease in lymphadenopathy, resulting in 1 IWCLL partial response (

248 owed an 11.6-cm pelvic mass, retroperitoneal lymphadenopathy, right hydronephrosis, and mesenteric tu

249 even patients; 29%), > or = 50% reduction of lymphadenopathy (seven of 22 patients; 32%), and > or =

250 cytosis and sinus histiocytosis with massive lymphadenopathy (SHML), characterized by severe tissue i

251 d enhancement of the septum, and mediastinal lymphadenopathy should raise the suspicion for CS.

252 , whereas patients with MRD-negative PR with lymphadenopathy showed a shorter PFS (31 months; P < .00

253 had an LR of 0.5 or less, but the absence of lymphadenopathy slightly decreased the likelihood of ear

254 statistically significant decrease in DNTs, lymphadenopathy, splenomegaly, and autoantibodies after

255 d.apoE(-/-) mice also displayed increases in lymphadenopathy, splenomegaly, and autoantibodies compar

256 Clinical manifestations include lymphadenopathy, splenomegaly, and autoimmune cytopenias

257 described a syndrome of chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmunity associat

258 ipients resulted in T and B cell activation, lymphadenopathy, splenomegaly, and the production of IgG

259 lta) in a patient who presented with chronic lymphadenopathy, splenomegaly, autoantibodies, elevated

260 Results from this study reveal significant lymphadenopathy, splenomegaly, elevated titers of anti-n

261 drome (ALPS) is characterized by early-onset lymphadenopathy, splenomegaly, immune cytopenias, and an

262 n of lymphocytes and childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias,

263 We found no significant difference in lymphadenopathy, splenomegaly, or anti-chromatin autoant

264 ighly elevated and 33% of patients exhibited lymphadenopathy, suggesting frequently the diagnosis of

265 nucleosis is reduced with the absence of any lymphadenopathy (summary sensitivity, 0.91; positive LR

266 ble and fertile but rapidly developed severe lymphadenopathy, systemic autoimmune disease, and thromb

267 rstood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and

268 B6.p18(-/-).lpr mice showed a greater lymphadenopathy than B6.Sle2c1.lpr mice, but their renal

269 uble deficiency of Bim and Bmf caused more B lymphadenopathy than loss of either BH3-only protein alo

270 tal role respectively in epidermotropism and lymphadenopathy that is observed in SS.

271 with lpr, resulting in a greatly accelerated lymphadenopathy that largely targeted T cells and mapped

272 nantly young males presenting with localized lymphadenopathy; the tumor shows high-grade cytology and

273 ic phenotype, characterized by splenomegaly, lymphadenopathy, thymic atrophy, and multiple abnormalit

274 Toxoplasmic lymphadenopathy (TL) is the most common clinical manifes

275 77 patients (6.5%), while hilar/mediastinal lymphadenopathy was found in 25 of 76 patients (33%).

276 easured up to 5 mm, and no additional pelvic lymphadenopathy was identified.

277 At presentation, generalized lymphadenopathy was noted in 76% of patients, and 89% ha

278 Lymphadenopathy was observed in 12% of patients.

279 Neither fever nor lymphadenopathy was observed.

280 Lymphadenopathy was seen in 1 case with gallbladder carc

281 ung, lacrimal and salivary glands, skin, and lymphadenopathy) was diminished.

282 psy in differentiating benign from malignant lymphadenopathy were 98.1%, 100%, and 98.7%, respectivel

283 cy in differentiating lymphoma from reactive lymphadenopathy were 98.5%, 100%, and 98.7%, respectivel

284 lar rash, and fever, pruritus, headache, and lymphadenopathy were also common.

285 f biliary dilatation, vascular invasion, and lymphadenopathy were assessed.

286 h T1-2 primary breast cancer and no palpable lymphadenopathy were enrolled in the randomised, multice

287 In this study, 132 patients with lymphadenopathy were investigated.

288 d enhancement of the septum, and mediastinal lymphadenopathy were more often see in those with CS (P<

289 s, reticular opacities, pleural effusion, or lymphadenopathy were not observed in any patient.

290 al border cortical destruction, and cervical lymphadenopathy were noted more frequently in the recurr

291 Declines in ALC and/or lymphadenopathy were observed in the majority of patient

292 f mice, the involvement of NALT and cervical lymphadenopathy were observed, indicating entry via both

293 Patients with cervical lymphadenopathy were prospectively enrolled between Apri

294 , and lymph-node aspirate (for patients with lymphadenopathy) were obtained for mycobacterial culture

295 ctively reduced the number of DN T cells and lymphadenopathy, whereas selective expansion of Treg by

296 mice developed progressive splenomegaly and lymphadenopathy with accumulation of engorged macrophage

297 phoma showed splenomegaly, hepatomegaly, and lymphadenopathy with involvement of bone marrow, thymus,

298 significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cel

299 onfirmed the lung lesion and the mediastinal lymphadenopathy without distant metastases.

300 Low attenuation mesenteric lymphadenopathy, without enlarged small bowel segments w